Since December 2019, a new disease named COVID-19 linked to a new coronavirus, SARS-CoV2 has emerged in China in the city of Wuhan, Hubei province, spreading very quickly to all 5 continents, and responsible for a pandemic. France is the third most affected country in Europe after Italy and Spain. Groups of patients at a higher risk of developing a severe form of COVID-19 have been defined: this include patients with immunosuppressive disease as cancer or patients with advanced cirrhosis of the liver. Coronavirus liver injury had been described with SARS-CoV 1 and MERS-CoV. There is no data on liver damage associated with COVID-19 infection for compensated or decompensated cirrhotic patients. The objectives of this project are to estimate the incidence of COVID-19 in hepatocellular carcinoma population, both hospital and ambulatory, and to study the impact on the frequency of severe forms, the prognosis, but also liver function, and the management of hepatocellular carcinoma, in this context of pandemic
Diagnostic Test: nasopharyngeal Covid 19 RT-PCR
nasopharyngeal Covid 19 RT-PCR
Inclusion Criteria:
- Patients with CHC and included in the French national prospective cohort CHIEF
- Hospital and ambulatory patients
- Infection confirmed by COVID-19 defined by a positive nasopharyngeal PCR or if PCR
COVID-19 negative : CT showing COVID-19 compatible pneumonia
- Suspected COVID-19 infection, not confirmed by COVID-19 PCR or chest CT, with no other
known cause of acute pneumonia.
Exclusion Criteria:
- Patient refusal
- Influenza only, confirmed by a diagnostic test
- Other proven causes of pneumonia and absence of COVID-19
CHU Amiens
Amiens, France
Investigator: Eric NGUYEN KHAC, Pr
Contact: (33)3 22 08 88 51
nguyen-khac.eric@chu-amiens.fr
Investigator:
Eric NGUYEN KHAC, Pr
(33)3 22 08 88 51
nguyen-khac.eric@chu-amiens.fr
Olivier GANRY, Pr
(33)3 22 08 83 76
ganry.olivier@chu-amiens.fr